Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A11QVV0
Thu, 23.05.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024
Ladenburg, Germany, 23 May 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that its management team will be participating [ … ]
Thu, 23.05.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024
Ladenburg, Germany, 23 May 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that its management team will be participating [ … ]
Thu, 25.04.2024
Heidelberg Pharma AG
Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024
First efficacy data from the clinical trial with HDP-101 in multiple myeloma
Professor Andreas Pahl becomes Chief Executive Officer
Successful financing activities
Sale of a portion of future royalties for Zircaix™ to HealthCare Royalty finances further develo [ … ]
Fri, 05.04.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
Ladenburg, Germany, 5 April 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that it will be hosting an R&D Webinar on 23 April 2024 at 16.00 CEST [ … ]
Fri, 05.04.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
Ladenburg, Germany, 5 April 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that it will be hosting an R&D Webinar on 23 April 2024 at 16.00 CEST [ … ]
Wed, 27.03.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
Ladenburg, Germany, 27 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that the US Food and Drug Administration (FDA) has g [ … ]
Mon, 25.03.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
First efficacy data from the clinical trial with HDP-101 in multiple myeloma
Expansion of the ADC technology platform to include further payloads
New Management Board team
Successful financing activities; sales revenue and other i [ … ]
Tue, 19.03.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty
Ladenburg, Germany, 19 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today ann [ … ]
Mon, 18.03.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study
Data from HDP-101 dose escalation shows first objective responses and partial remissions in Cohort 5
Amended protocol includes expanded Cohort 6 with dose optimization, including three parallel arms a [ … ]
Wed, 06.03.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
Ladenburg, Germany, 6 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs) will be presenting first efficacy data on its P [ … ]